New drug combo offers Surgery-Free option for elderly breast cancer patients
NCT ID NCT02760030
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 14 times
Summary
This study tested a combination of two hormone-blocking drugs (fulvestrant and palbociclib) in 14 elderly patients with hormone-sensitive breast cancer who either could not undergo surgery due to frailty or chose not to have it. The goal was to see if this drug pair could control the cancer for at least one year without needing surgery. Results showed the treatment was generally manageable, offering a non-surgical option for this older population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IA BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Western University
Cleveland, Ohio, 44106, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
St. Elizabeth Healthcare
Edgewood, Kentucky, 41017, United States
Conditions
Explore the condition pages connected to this study.